许永 - 中国科学院广州生物医药与健康研究院 -

个人简介

2001.9-2004.7 中国科学院上海药物研究所，药物发现与设计中心，有机化学，博士； 2004.8-2006.5 中国科学院上海有机化学研究所，生命有机国家重点实验室，计算生物学，博士后 2006.6-2011.8 美国文安诺研究所（Van Andel Institute），结构生物学与药物发现中心，计算与结构生物学，博士后 2011.9-今中国科学院广州生物医药与健康研究院，研究员，课题组长，博士生导师，化学生物学与药物研究中心主任（2021年起） 2016年-今广东省生物医药计算重点实验室，副主任

研究领域

综合运用药物分子设计、药物化学、结构生物学、计算生物学和药理学等多学科交叉策略，开展针对恶性肿瘤等疾病的新药物靶标发现与确证、药物作用机制研究以及创新药物开发研究

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Qiu Li#, Benqiang Yao#, Shiting Zhao, Zhou Lu, Yan Zhang, Qiuping Xiang, Xishan Wu, Haonan Yu, Cheng Zhang, Junhua Li, Xiaoxi Zhuang, Donghai Wu, Yong Li, Yong Xu. Discovery of a Highly Selective and H435R Sensitive Thyroid Hormone Receptor Agonist. J Med Chem. 2022 May 4. Doi: 10.1021/acs.jmedchem.2c00144. Li J#, Zhang C#, Xu H, Wang C, Dong R, Shen H, Zhuang X, Chen X, Li Q, Lu J, Zhang M, Wu X, Loomes KM, Zhou Y, Zhang Y, Liu J, Xu Y. Structure- Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors. J Med Chem.2022, 65, 5760-5799. Xiang Q, Wang C, Wu T, Zhang C, Hu Q, Luo G, Hu J, Zhuang X, Zou L, Shen H, Wu X, Zhang Y, Kong X, Liu J, Xu Y. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. J Med Chem. 2022, 65, 785-810 Wu X#, Shen H#, Zhang Y#, Wang C, Li Q, Zhang C, Zhuang X, Li C, Shi Y, Xing Y, Xiang Q, Wu D, Liu J, Xu Y*. Discovery and characterization of benzimidazole derivative XY123 as a selective, and orally available ROR inverse agonist. J Med Chem. 2021, 64, 8775-8797 Wu X, Zhang Y, Xu Y*. Discovery of the First Low Nanomolar Liver Receptor Homolog-1 (LRH-1) Agonist. J Med Chem. 2019, 62, 11019-11021 Zhang Y#, Wu X#, Xue X#, Li C, Wang J, Wang R, Zhang C, Wang C, Shi Y, Zou L, Li Q, Huang Z, Hao X, Loomes K, Wu D, Chen HW, Xu J, Xu Y*. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable ROR Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.J Med Chem. 2019, 62, 4716-4730 Zhang M#, Zhang Y#, Song M#, Xue X, Wang J, Wang C, Zhang C, Li C, Xiang Q, Wu X, Wu C, Dong B, Xue We, Zhou Y, Chen H, Wu D, Ding K, Xu Y*. Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors as Potential Treatment for Castration-Resistant Prostate Cancer (CRPC). J Med Chem, 2018. 61, 3037-3058 Wang, J.; Zou, J.X.; Xue, X.; Cai, D.; Zhang, Y.; Duan, Z.; Xiang, Q.; Yang, J.C.; Louie, M.C.; Borowsky, A.D.; Gao, A.C,; Evans, C.P.; Lam, K.S.; Xu, J.; Kung, H.J.; Evans, R.M.; Xu, Y.*; Chen, H.W.*; ROR- drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med, 2016, 22: 488-496. Xue, X#.; Zhang, Y#.; Liu, Z#.; Song, M.; Xing, Y.; Xiang, Q.; Wang, Z.; Tu, Z.; Zhou, Y.; Ding, K.; Xu Y*. Discovery of benzo[cd]indol-2(1H)-ones as potent and specific BET bromodomain inhibitors: structure-based virtual screening, optimization, and biological evaluation. J Med Chem, 2016, 59, 1565-1579 Cao, M.; Liu, X.; Zhang, Y.; Xue, X.; Zhou, X. E.; Melcher, K.; Gao, P.; Wang, F.; Zeng, L.; Zhao, Y.; Zhao, Y.; Deng, P.; Zhong, D.; Zhu, J. K.*; Xu, H. E.*; Xu, Y*. An ABA-mimicking ligand that reduces water loss and promotes drought resistance in plants.